Nebenwirkungen · RoActemra
RoActemra 20 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-120239 · Präparat HOS-095117
Tabulated list of adverse reactions Adverse reactions from clinical trials and/or post-marketing experience with tocilizumab based on spontaneous case reports, literature cases and cases from non-interventional trial programs are listed in Table 1 and in Table 2 by MedDRA system organ class (SOC). The corresponding frequency category for each adverse reaction is based on the following convention: very common ( ≥ 1/10); common ( ≥ 1/100 to < 1/10), uncommon ( ≥ 1/1 000 to < 1/100), rare ( ≥ 1/10 000 to < 1/1 000), very rare ( < 1/10 000), and frequency not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage f096a6f9e0b989a86675a96813642a54f24847272f7f2ab451b4956473271c1e · Zeichen 514–1228 im Abschnitt